PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives $53.40 Average PT from Analysts

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $53.40.

Several analysts have issued reports on PRCT shares. Leerink Partners restated an “outperform” rating and issued a $55.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Wall Street Zen raised PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Bank of America reaffirmed a “neutral” rating and set a $38.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a research report on Monday, December 8th. Finally, UBS Group began coverage on shares of PROCEPT BioRobotics in a research report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective on the stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vega Investment Solutions lifted its position in PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after purchasing an additional 265 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new position in shares of PROCEPT BioRobotics in the 3rd quarter valued at approximately $30,000. AlphaQuest LLC lifted its holdings in shares of PROCEPT BioRobotics by 1,262.5% during the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after acquiring an additional 1,010 shares during the period. CWM LLC boosted its position in shares of PROCEPT BioRobotics by 40.7% during the 2nd quarter. CWM LLC now owns 1,228 shares of the company’s stock worth $71,000 after acquiring an additional 355 shares in the last quarter. Finally, Center for Financial Planning Inc. bought a new position in PROCEPT BioRobotics in the fourth quarter valued at approximately $40,000. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Stock Performance

Shares of PRCT stock opened at $29.21 on Friday. PROCEPT BioRobotics has a 12 month low of $26.66 and a 12 month high of $70.80. The company’s fifty day simple moving average is $32.00 and its 200-day simple moving average is $35.36. The firm has a market cap of $1.63 billion, a PE ratio of -19.09 and a beta of 0.99. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.